^○Leo GOTOH^{1, 2}, Yuma OGUSHI², Takako KAWAGUCHI², Akihito HATANAKA², Kentaro KIRA², Hiroaki KAWASAKI^{1, 2} (1. Lab. of Neuroscience, Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan, 2. Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan)

^○Hiroki SHIKANAI¹, Robel GHEBREAB², Takayuki YOSHIDA², Akitoyo HISHIMOTO³, Mitsuhiro YOSHIOKA², Takeshi IZUMI¹ (1. Department of Pharmacology, Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Hokkaido, Japan, 2. Department of Neuropharmacology, Graduate School of Medicine, Hokkaido University, 3. Department of Psychiatry, Kobe University, Graduate School of Medicine)

^○Rumi SHINCHI, Yu ARAKI, Ryo FUKUMORI, taku YAMAGUCHI (Department of Pharmacotherapeutics and Neuropsychopharmacology, Faculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo, Nagasaki, Japan)

^○Hiroe SUZUKI, Natsuko HITORA-IMAMURA, Masabumi MINAMI (Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University)

^○Hajime MIYANISHI¹, Kyosuke UNO^{1, 2}, Shin-ichi MATSUMURA^{3, 4}, Atsumi NITTA¹ (1. Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Medicine and Pharmaceutical Sciences, Toyama　unuversity, Toyama , 2. Laboratory of Molecular Pharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Japan, 3. Division of Neurological Gene Therapy, Open Innovation Center, Jichi Medical University, Shimotsuke, Japan, 4. Center for Gene & Cell Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan)

^○Kazuki TOKORO¹, Kyosuke UNO^{1, 2}, Shin-ichi MURAMASTU^{3, 4}, Atsumi NITTA¹ (1. Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan., 2. Laboratory of molecular pharmacology faculty of pharmaceutical science, University of Setsunan, Osaka, Japan, 3. Division of Neurology, Department of Medicine, Jichi Medical University, Shimotsuke 329-0498, JAPAN, 4. Center for Gene and Cell Therapy, Institute of Medical Science, The University of Tokyo, Tokyo 113-8564,JAPAN)

^○Fumitaka NAKANO¹, Kyosuke UNO^{2, 3}, Kazuki TOKORO², Hiroki TAKEMOTO¹, Atsumi NITTA^{1, 2} (1. Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan, 2. Department of Pharmaceutical Therapy and Neuropharmacology, Graduate School of Medicine and Pharmaceutical Science, University of Toyama, Toyama, Japan, 3. Laboratory of molecular pharmacology faculty of pharmaceutical sciences, University of Setsunan, Osaka, Japan)

^○Kouhei YOSHINO¹, Yasunori ODA¹, Makoto KIMURA¹, Masahito NANGAKU¹, Yukihiko SHIRAYAMA², Masaomi IYO¹ (1. Department of Psychiatry, Chiba University Graduate School of Medicine, 2. Department of Psychiatry, Teikyo University Chiba Medical Center)

^○Kumi SUZUKI¹, Makiko MIYAMOTO¹, June TOGAMI¹, Daisuke NISHIZAWA², Kazutaka IKEDA², Eizi YOSHIHARA¹, Kazuhiko IWAHASHI^{1, 2, 3} (1. Lab. of Physiology(Project of Neurophysiology),Course of Environmental Health Science, Graduate School of Environmental Health, Azabu University, Kanagawa, Japan, 2. Addictive Substance Project,Department of Psychiatry and Behavioral Science, Tokyo Metropolitan Institute of Medical Science,Tokyo,Japan, 3. Health Administration Center,Azabu University,Kanagawa,Japan)

^○Hiroki FURUIE¹, Masatoshi UKEZONO^{1, 2, 3}, Mitsuhiko YAMADA¹ (1. Department of Neuropsychopharmacology, National Institute of Mental Health, National Center of Neurology and Psychiatry, 2. Toyo Rice Corporation, 3. Medical Sciences Innovation Hub Program, RIKEN)

^○Takumi NAKAJIMA¹, Kequan FU^{1, 2}, Yoshiaki MIYAMOTO¹, Atsumi NITTA¹ (1. Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan, 2. Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, China)

^○Ryo FUKUMORI, Kensaku OTA, Tsuneyuki YAMAMOTO, Taku YAMAGUCHI (Department of Pharmacotherapeutics, Faculty of Pharmaceutical Sciences, Nagasaki International University)

^○Yuki HONSHUKU, Ryoki SAITO, Takuji SOGA, Natsuko HITORA-IMAMURA, Masabumi MINAMI (Lab. of Pharmacology, Department of Pharmacy, Hokkaido university, Hokkaido, Japan)

^○June TOGAMI¹, Kumi SUZUKI¹, Makiko MIYAMOTO¹, Daisuke NISHIZAWA², Kazutaka IKEDA², Atsuko KAWAI³, Eiji YOSHIHARA¹, Kazuhiko IWAHASHI^{1, 2, 4} (1. Lab. of Physiology, Department of Medical Technology, Graduate School of Environmental Health, Azabu University, Kanagawa, Japan, 2. Addictive Substance Project, Department of Psychiatry and Behavioral Science, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan, 3. Koutokukai Total Health Clinic, Yamagata, Japan, 4. Health Administration center, Azabu University, Kanagawa, Japan)

^○Makiko MIYAMOTO¹, Kumi SUZUKI¹, June TOGAMI¹, Eiji YOSHIHARA¹, Daisuke NISHIZAWA², Atsuko KAWAI³, Kazutaka IKEDA², Kazuhiko IWAHASHI^{1, 2, 4} (1. Laboratory of Physiology (Project of Neurophysiology), Course of Environmental Health Science, Graduate School of Environmental Health, Azabu University, Kanagawa, Japan, 2. Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan, 3. Koutokukai Total Health Clinic, Yamagata, Japan, 4. Health Administration Center, Azabu University, Kanagawa, Japan)

^○Yuka KUSUI¹, Kyosuke UNO^{1, 2}, Shin-ichi MURAMATSU^{3, 4}, Atsumi NITTA¹ (1. Lab. of Pharmaceutical Therapy and Neuropharmacology,Department of Pharmaceutical Sciences,University of Toyama,Toyama,Japan , 2. Laboratory of Molecular Pharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, 3. Division of Neurological Gene Therapy, Open Inovation Center, Jichi Medical University, 4. Center for Gene & Cell Therapy, Institute of Medical Science)

^○Fan WANG¹, Kyohei YAMADA¹, Kyosuke UNO¹, Hiroshi MARUYAMA¹, Noboru MOTOYAMA², Wakako MARUYAMA³, Atsumi NITTA¹ (1. Department of pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School and Pharmaceutical Sciences, University of Toyama, Toyama, Japan, 2. Department of Health and Nutrition Faculty of Psycological & Physical Science Aichi Gakuin University, Aichi, JapanDepartment of Health and Nutrition Faculty of Psycological & Physical Science Aichi Gakuin University, Aichi, Japan, 3. Laboratory of Biochemistry, Department of Human Nutrition, Sugiyama Jogakuen University, Aichi, Japan)

^○Kazuo TAKAHAMA¹, Taishi HAMAGUCHI², Ryo KAWAHARA², Takashi SAITO³, Takaomi SAIDO³, Shogo MISUMI² (1. Fuculty of Health Science, Kumamoto Health Science University, 2. Department of Environmental & molecular health science, Graduate School of Pharmaceutical Sciences, Kumamoto University, 3. Laboratory　for Proteolytic Neuroscience, RIKEN Center for　Brain Science)

^○Masaki NAGAO¹, Naoki IMAGAWA², Takuya WATANABE^{1, 2}, Kaori KUBOTA^{1, 2}, Shutaro KATSURABAYASHI², Katsunori IWASAKI^{1, 2} (1. Institute for Aging and Brain Sciences, Fukuoka University, Fukuoka, Japan , 2. Department of Neuropharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan)

^○Katsunori AZUMA¹, Meriem HADDAR¹, Kyousuke UNO², Shin-ichi MURAMATSU^{3, 4}, Atsumi NITTA¹ (1. Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan., 2. Laboratory of molecular pharmacology faculty of pharmceutical sciendes, University of Setsunan, Osaka, Japan, 3. Division of Neurology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan, 4. Center for Gene and Cell Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan)

^○Takeru SUZUKI^{1, 2}, Daisuke JOHO^{1, 2}, Masaki KAKEYAMA^{1, 2} (1. Lab. of Environmental Brain Science, Graduate School of Human Sciences, Waseda University, Saitama, Japan, 2. Research Institute for Environmental Medical Sciences, Waseda University, Saitama, Japan)

^○Daisuke JOHO^{1, 2}, Takeru SUZUKI^{1, 2}, Masaya FUJIWARA², Takashi SAITO³, Takaomi SAIDO³, Masaki KAKEYAMA^{1, 2} (1. Lab. of Environmental Brain Science, Graduate School of Human Sciences, Waseda University, Saitama, Japan, 2. Research Institute for Environmental Medical Sciences, Waseda University, Saitama, Japan, 3. Lab. for Proteolytic Neuroscience, RIKEN Center for Brain Science, Saitama, Japan)

^○Kenichi TANAKA¹, Yusuke HAMADA¹, Daisuke SATO¹, Michiko NARITA¹, Daisuke OIKAWA¹, Hideki TAMURA², Akihiro YAMANAKA³, Naoko KUZUMAKI¹, Minoru NARITA^{1, 2} (1. Dept. Pharmacol., Hoshi Univ., Tokyo, Japan, 2. L-StaR, Hoshi Univ., Tokyo, Japan, 3. Dept. Neurosci.II, RIEM Nagoya Univ., Nagoya, Japan)

^○Ko MIYOSHI^{1, 2}, Sarina HAN³, Sho SHIKADA¹, Yinshengzhuoma WANG¹, Yuanyuan QIN ¹, Genki AMANO¹, Takeshi YOSHIMURA¹, Taiichi KATAYAMA¹ (1. Department of Child Development and Molecular Brain Science, United Graduate School of Child Development, Osaka University, Suita, Japan, 2. Molecular Research Center for Child Mental Development, United Graduate School of Child Development, Osaka University, Suita, Japan, 3. Department of Biofunctional Imaging, Hamamatsu University School of Medicine, Hamamatsu, Japan)

^○Megumi FURUKAWA¹, Nobuo IZUMO², Kotaro SHINDO², Akihide SUMINO², Kosuke HAYAMIZU², Makoto NAKANO², Takayuki MANABE³, Kazuho OKUDAIRA¹, Yasuo WATANABE² (1. Center for pharmaceutical education, Yokohama University of Pharmacy, Kanagawa, Japan, 2. Genaral Health Medical Center, Yokohama University of Pharmacy, Kanagawa, Japan, 3. Lab. Neuroanatomy and Neuropharmacol. Research Field of professional Basic Medicine, Department of Nursing, Faculty of Nursing, Chukyogakuin Unibersity, Gifu, Japan)

^○Keiko IKEMOTO (Department of Psychiatry, Iwaki City Medical Center)

^○Hisashi YAMADA^{1, 2}, Mikuni MOTOYAMA¹, Tomoko SHIINO², Hasegawa NAOMI², Yota UNO², Koichiro WATANABE³, Ken INADA⁴, Ryota HASHIMITO², Hisato MATSUNAGA¹ (1. Department of Neuropsychiatry, Hyogo College of Medicine, 2. Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, 3. Department of Neuropsychiatry, Kyorin University School of Medicine, 4. Dept. of Psychiatry, Tokyo Women's Medical University)

^○Mikuni MOTOYAMA¹, Hisashi YAMADA^{1, 2}, Tomoko SHIINO², Naomi HASEGAWA², Yota UNO², Ken INADA³, Koichiro WATANABE⁴, Ryota HASHIMOTO², Hisato MATSUNAGA¹ (1. Department of Neuropsychiatry, Hyogo College of Medicine, 2. Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, 3. Department of Psychiatry, Tokyo Women's Medical University, 4. Department of Neuropsychiatry, Kyorin University School of Medicine)

^○Kazutaka OHI^{1, 2}, Takamitsu SHIMADA¹, Yuzuru KATAOKA ¹, Yoko KOIDE¹, Takashi UEHARA¹, Hiroaki OKUBO¹, Yasuhiro KAWASAKI¹ (1. Department of Neuropsychiatry, Kanazawa Medical University, Ishikawa, Japan, 2. Medical Research Institute, Kanazawa Medical University, Ishikawa, Japan)

^○Takamitsu SHIMADA^{1, 2}, Kazutaka OHI^{1, 3}, Yuzuru KATAOKA¹, Yoko KOIDE¹, Hiroaki OKUBO¹, Takashi UEHARA¹, Yasuhiro KAWASAKI¹ (1. Department of Neuropsychiatry, Kanazawa Medical University, Ishikawa, Japan, 2. Okabe Hospital, Ishikawa, Japan, 3. Medical Research Institute, Kanazawa Medical University, Ishikawa, Japan)

^○Yuzuru KATAOKA¹, Kazutaka OHI^{1, 2}, Takamitsu SHIMADA¹, Hiroaki OKUBO¹, Takashi UEHARA¹, Yasuhiro KAWASAKI¹ (1. Department of psychiatry, Kanazawa Medical University, Ishikawa, Japan, 2. Medical Research Institute, Kanazawa Medical University, Ishikawa, Japan)

^○Junya FUJINO^{1, 2}, Shisei TEI^{1, 2, 3, 4}, Ryosaku KAWADA², Kathryn F. JANKOWSKI⁵, Toshiya MURAI², Hidehiko TAKAHASHI^{1, 2, 6} (1. Medical Institute of Developmental Disabilities Research, Showa University, 2. Department of Psychiatry, Graduate School of Medicine, Kyoto University, 3. Institute of Applied Brain Sciences, Waseda University, 4. School of Human and Social Sciences, Tokyo International University, 5. Department of Psychology, University of Oregon, 6. Department of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University)

^○Akira IWANAMI¹, Kazuhiko SAITO², Masakazu FUJIWARA³, Daiki OKUTSU⁴, Hironobu ICHIKAWA⁵ (1. Department of Psychiary, Showa University, School of Medicine, 2. Aiiku Institute, AI-Iku counseling Office, 3. SHIONOGI & CO., LTD., 4. SHIONOGI & CO., LTD., 5. JDDnet)

^○Akira IWANAMI¹, Kazuhiko S², Masakazu F³, Daiki OKUTSU⁴, Hironobu ICHIKAWA⁵ (1. Department of Psychiary, Showa University, School of Medicine, 2. Aiiku Institute, AI-Iku counseling Office, 3. SHIONOGI & CO., LTD., 4. SHIONOGI & CO., LTD., 5. JDDnet)

^○Atsushi KITAMURA, Takeshi TAKAGAKI, Daisuke NEMOTO, Yoshiko TOMITA, Hironori NISHIBE, Hiroyoshi KAKUYAMA, Katsunori MARUTA (Clinical Research, Drug Development Division, Sumitomo Dainippon Pharma Co., Ltd.)

^○Masayasu TANAKA, Takayuki MURAKAMI (Formulation Research & Development Lab. Sumitomo Dainippon Pharma Co.,Ltd. ,Osaka, Japan)

^○Tomoyuki MURANO, Hideo HAGIHARA, Tsuyoshi MIYAKAWA (Division of Systems Medical Science, Institute for Comprehensive Medical Science, Fujita Health University)

^○Matsuhiko OKA¹, Koki ITO¹, Minori KOGA², Ichiro KUSUMI¹ (1. 神経病態学分野精神医学教室, 2. 精神科学講座)

^○Toshiko KUCHIIWA^{1, 2}, Satoshi KUCHIIWA^{1, 2} (1. Dep. Neuroanatomy,Grad. Sch. Med. Dent. Sci., Kagoshima Univ., 2. Dept. Clinical Psychology, Grad. Sch. Human Sci., Kagoshima Immaculate Heart Univ.)

^○Toshihiro ENDO^{1, 2}, Hidenori NAKAMURA³ (1. Phenovance Research and Technology LLC, 2. Faculty of Medicine, University of Tsukuba, 3. atDose Co., Ltd.)

^○Toshihiro ENDO^{1, 2}, Seico BENNER³, Chiharu TOHYAMA² (1. Phenovance Research and Technology LLC, 2. Faculty of Medicine, University of Tsukuba, 3. Department of Psychiatry, Hamamatsu University School of Medicine)

^○Hideo HAGIHARA, Hirotaka SHOJI, Yoshihiro TAKAMIYA, Tsuyoshi MIYAKAWA (Division of Systems Medicsl Science, Institute for Comprehensive Medical Science, Fujita Health University, Aichi, Japan)

^○Kaori ISHII^{1, 2}, Yuko NAKATAKE^{2, 3}, Misa YAMADA², Hiroki FURUIE², Kazumi YOSHIZAWA¹, Mitsuhiko YAMADA² (1. Laboratory of Pharmacology and Therapeutics, Department of Pharmacy, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2. Department of Neuropsychopharmacology, National Institute of Mental Health, National Center of Neurology and Psychiatry, 3. Laboratory of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Tokyo University of Science)

^○Ryuto HARA, Tatsuhiro TAKEHARA, Daiki TAKAHASHI, Saki MINAMI, Taiju AMANO, Masabumi MINAMI (Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan)

^○Ran INOUE, Xiance NI, Hisashi MORI (Department of Molecular Neuroscience, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama)

^○Naoki YAMAUCHI, Hiroshi NOMURA, Taiju AMANO, Masabumi MINAMI (Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University.)

^○Saya ARAKAKI, Keisuke SAKASAI, Natsuko HITORA-IMAMURA, Masabumi MINAMI (Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Hokkaido, Japan)

^○Jingzhu LIAO¹, Taku NAGAI¹, Bolati WULAER¹, Toshitaka NABESHIMA^{2, 3}, Kiyofumi YAMADA¹ (1. Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 2. Advanced Diagnostic System Research Laboratory Fujita Health University, Graduate School of Health Sciences, 3. Aino University)

^○Manabu TOYOSHIMA, Tetsuo OHNISHI, Takeo YOSHIKAWA (Laboratory for Molecular Psychiatry RIKEN Center for Brain Science)

^○Hitomi SHIMIZU¹, Minori OZEKI¹, Miyu UWANO¹, Katsuaki HIRAOKA¹, Naho HAYASHI¹, Naoto HORIE¹, Shouhei OHNO¹, Chikako WAGA¹, Kenji SAKIMURA², Shigeo UCHINO¹ (1. Department of Biosciences, School of Science and Engineering, Teikyo University, 2. Brain Research Institute, Niigata University)

^○Haruhide KIMURA, Takashi ISHIKAWA, Hiroshi YUKITAKE, Motohisa SUZUKI (Neuroscience Drug Discovery Unit, Research, Takeda Parmaceutical Company Limited)

^○Masaomi IYO¹, Jun ISHIGOOKA², Masatoshi NAKAMURA³, Reiko SAKAGUCHI⁴, Keisuke OKAMOTO⁵, Tadashi NOSAKA⁶, Teruhiko HIGUCHI ^{7, 8} (1. Department of Psychiatry, Graduate School of Medicine, Chiba University, Japan, 2. Institute of CNS Pharmacology, Japan, 3. Data Science, Sumitomo Dainippon Pharma Co., Ltd., Japan, 4. Clinical Research, Sumitomo Dainippon Pharma Co., Ltd., Japan, 5. Clinical Operations, Sumitomo Dainippon Pharma Co., Ltd., Japan, 6. Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd., Japan, 7. Japan Depression Center, Japan, 8. The National Center of Neurology and Psychiatry, Japan)

^○Tadafumi KATO¹, Jun ISHIGOOKA², Mari MIYAJIMA³, Kei WATABE⁴, Takahiro MASUDA⁵, Teruhiko HIGUCHI^{6, 7} (1. Laboratory for Molecular Dynamics of Mental Disorders, RIKEN Center for Brain Science, Tokyo, Japan, 2. Institute of CNS Pharmacology, Japan, 3. Clinical Research, Sumitomo Dainippon Pharma Co., Ltd., Japan, 4. Data Science, Sumitomo Dainippon Pharma Co., Ltd., Japan, 5. Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd., Japan, 6. Japan Depression Center, Japan, 7. The National Center of Neurology and Psychiatry, Japan)

^○Teruhiko HIGUCHI^{1, 2}, Jun ISHIGOOKA³, Mari MIYAJIMA⁴, Kei WATABE⁵, Takahiro MASUDA⁶, Tadafumi KATO⁷ (1. Japan Depression Center, Japan, 2. The National Center of Neurology and Psychiatry, Japan, 3. Institute of CNS Pharmacology, Japan, 4. Clinical Research, Sumitomo Dainippon Pharma Co., Ltd., Japan, 5. Data Science, Sumitomo Dainippon Pharma Co., Ltd., Japan, 6. Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd., Japan, 7. Laboratory for Molecular Dynamics of Mental Disorders, RIKEN Center for Brain Science, Japan)

^○Jun ISHIGOOKA¹, Teruhiko HIGUCHI^{2, 3}, Mari MIYAJIMA⁴, Kei WATABE⁵, Takahiro MASUDA⁶, Tadafumi KATO⁷ (1. Institute of CNS Pharmacology, Japan, 2. Japan Depression Center, Japan, 3. The National Center of Neurology and Psychiatry, Japan, 4. Clinical Research, Sumitomo Dainippon Pharma Co., Ltd., Japan, 5. Data Science, Sumitomo Dainippon Pharma Co., Ltd., Japan, 6. Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd., Japan, 7. Laboratory for Molecular Dynamics of Mental Disorders RIKEN Center for Brain Science, Japan)

^○Yuma Yokoi¹, Naoki Yoshimura¹, Kenji Hatano¹, Takayuki Abe², Atsuo Nakagawa², Ken Inada³, Tomiki Sumiyoshi¹, Koichiro Watanabe⁴, Takashi Tsuboi⁴, Yumiyo Morokawa⁵, Akira Iwanami⁶, Masaru Mimura⁷, Toshiaki Furukawa⁸, Gentaro Nishioka⁹, Hideki Oi¹, Kazuyuki Nakagome¹ (1. National Center of Neurology and Psychiatry, 2. Keio University Hospital Clinical and Translational Research Center, 3. Department of Psychiatry, Tokyo Women’s Medical University, 4. Department of Neuropsychiatry, Kyorin University School of Medicine, 5. Seimou Hospital Clinical Medicine Research Center, 6. Department of Psychiatry, Showa Karasuyama Hospital, 7. Department of Neuropsychiatry, Keio University School of Medicine, 8. Departments of Health Promotion and Human Behavior and of Clinical Epidemiology Kyoto University Graduate School of Medicine, 9. Kawaguchi Clinic)